Serelaxin: Difference between revisions

Jump to navigation Jump to search
(Created page with "{{Drugbox | IUPAC_name = L-Serine, L-α-aspartyl-L-seryl-L-tryptophyl-L-methionyl-L-α-glutamyl-L-α-glutamyl-L-valylL-isoleucyl-L-lysyl-L-leucyl-L-cysteinylglycyl-L-arginyl-L...")
 
m (Protected "Serelaxin": Bot: Protecting all pages from category Drug ([Edit=Allow only administrators] (indefinite) [Move=Allow only administrators] (indefinite)))
 
(2 intermediate revisions by one other user not shown)
Line 21: Line 21:
| molecular_weight = 5963 g/mol  
| molecular_weight = 5963 g/mol  
}}
}}
__NOTOC__
{{SI}}
{{CMG}}; {{AE}} {{KS}}


'''Serelaxin''' ('''RLX030''') is an investigational drug for the treatment of acute [[heart failure]] (AHF), targeting the [[relaxin receptor]]. Serelaxin is a recombinant form of human [[relaxin]]-2, a hormone that (among other functions) is produced during pregnancy and mediates the haemodynamic changes that occur during this time,<ref name="Spreitzer" /><ref name="aerztezeitung" /> such as increased blood output of the heart and blood flow in the kidney.<ref name="pmid21613576" />  Human-relaxin-2 mediates vasodilation (widening of blood vessels) by increasing the production of [[nitric oxide]] (NO), a potent [[vasodilator]].<ref name="Tousoulis" />  Activation of the relaxin receptor [[RXFP1]] activates several enzymes in a [[phosphorylation cascade]] that eventually results in the activation of NO synthase in endothelial cells and the subsequent production of NO.<ref name="Bathgate" />  Relaxin can also bind to a secondary receptor, endothelial B receptor,{{Clarify|date=March 2014}} which is upregulated as a result of the previous pathway.<ref name="Miyares" />  Relaxin binding to endothelial B receptor on endothelial cells also induces vasodilation.<ref name="Teichman1" />
==Overview==


Relaxin causes vasodilation by an indirect mechanism, where it inhibits the potent vasoconstrictors angiotensin II and endothelin.<ref name="Teichman2" /> 
'''Serelaxin''' ('''RLX030''') is an investigational drug for the treatment of acute [[heart failure]] (AHF), targeting the [[relaxin receptor]]. Serelaxin is a recombinant form of human [[relaxin]]-2, a hormone that (among other functions) is produced during pregnancy and mediates the haemodynamic changes that occur during this time, such as increased blood output of the heart and blood flow in the kidney.  Human-relaxin-2 mediates vasodilation (widening of blood vessels) by increasing the production of [[nitric oxide]] (NO), a potent [[vasodilator]].  Activation of the relaxin receptor [[RXFP1]] activates several enzymes in a [[phosphorylation cascade]] that eventually results in the activation of NO synthase in endothelial cells and the subsequent production of NO. Relaxin can also bind to a secondary receptor, endothelial B receptor, which is upregulated as a result of the previous pathway.  Relaxin binding to endothelial B receptor on endothelial cells also induces vasodilation.
In addition to vasodilation, the effects of relaxin are also seen in the kidneys, by significantly increasing [[creatinine]] clearance,<ref name="Ponikowski" /> which is a measure of kidney function, as well as increased renal blood flow.<ref name="Teichman1" />
 
Relaxin also functions as a cardiac stimulant.<ref name="Bathgate" />  Studies have demonstrated that relaxin increases calcium sensitivity of cardiac [[myofilament]]s as well as increasing phosphorylation of the myofilaments by [[protein kinase C]] (PKC).<ref name="Shaw" /> These modifications both function to increase the force generated by the myofilaments without increasing the energy consumption of the cardiac myocytes.<ref name="Shaw" />  Thus relaxin and serelaxin can increase [[stroke volume]], the amount of blood pumped per heart beat, without increasing the energy demand on the already strained heart of acute heart failure patients.
Relaxin causes vasodilation by an indirect mechanism, where it inhibits the potent vasoconstrictors angiotensin II and endothelin.
In addition to vasodilation, the effects of relaxin are also seen in the kidneys, by significantly increasing [[creatinine]] clearance, which is a measure of kidney function, as well as increased renal blood flow.
Relaxin also functions as a cardiac stimulant. Studies have demonstrated that relaxin increases calcium sensitivity of cardiac [[myofilament]]s as well as increasing phosphorylation of the myofilaments by [[protein kinase C]] (PKC).  These modifications both function to increase the force generated by the myofilaments without increasing the energy consumption of the cardiac myocytes. Thus relaxin and serelaxin can increase [[stroke volume]], the amount of blood pumped per heart beat, without increasing the energy demand on the already strained heart of acute heart failure patients.


==Acute heart failure==
==Acute heart failure==
Serelaxin is currently undergoing clinical trials in patients with acute heart failure,<ref name="Teerlink" /> and is being developed by [[Novartis]].  Serelaxin has completed several clinical trials as a therapy for AHF.  Phase I trials examined safety and tolerability,<ref name="Du" /> while phase II trials evaluated its haemodynamic effects and symptom relief.  The Pre-RELAX-AHF phase II trial administered a dose of 30&nbsp;µg/kg/day and showed a decrease in blood pressure, improved [[dyspnoea]], and increased renal blood flow.<ref name="Teichman1" /> In phase III the RELAX-AHF trial gave a 48hr intravenous infusion of the same dose.<ref name="King" /> It significantly improved patients' dyspnoea, resulted in a 30% reduction in worsening of heart failure symptoms, a decreased hospital stay and a reduction in signs and symptoms of congestion.<ref name="Teerlink" /><ref name="Filippatos" />  The FDA has granted serelaxin "breakthrough therapy" designation, meant to expedite the development and review of drugs for life threatening conditions and is set to be reviewed in February 2014.<ref name="Novartis" />
Serelaxin is currently undergoing clinical trials in patients with acute heart failure, and is being developed by Novartis.  Serelaxin has completed several clinical trials as a therapy for AHF.  Phase I trials examined safety and tolerability, while phase II trials evaluated its haemodynamic effects and symptom relief.  The Pre-RELAX-AHF phase II trial administered a dose of 30&nbsp;µg/kg/day and showed a decrease in blood pressure, improved [[dyspnoea]], and increased renal blood flow.  In phase III the RELAX-AHF trial gave a 48hr intravenous infusion of the same dose.  It significantly improved patients' dyspnoea, resulted in a 30% reduction in worsening of heart failure symptoms, a decreased hospital stay and a reduction in signs and symptoms of congestion. The FDA has granted serelaxin "breakthrough therapy" designation, meant to expedite the development and review of drugs for life threatening conditions and is set to be reviewed in February 2014.


== References ==
== References ==
{{reflist|35em|refs=
{{reflist|2}}
<ref name="Teerlink">{{cite journal|last=Teerlink|first=John R|coauthors=Cotter, Gad; Davison, Beth A; Felker, G Michael; Filippatos, Gerasimos; Greenberg, Barry H; Ponikowski, Piotr; Unemori, Elaine; Voors, Adriaan A; Adams, Kirkwood F; Dorobantu, Maria I; Grinfeld, Liliana R; Jondeau, Guillaume; Marmor, Alon; Masip, Josep; Pang, Peter S; Werdan, Karl; Teichman, Sam L; Trapani, Angelo; Bush, Christopher A; Saini, Rajnish; Schumacher, Christoph; Severin, Thomas M; Metra, Marco|title=Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial|journal=The Lancet|date=1 November 2012|doi=10.1016/S0140-6736(12)61855-8|url=http://www.sciencedirect.com/science/article/pii/S0140673612618558}}</ref>
<ref name="Spreitzer">{{cite journal| author = H. Spreitzer| date = 4 March 2013| title = Neue Wirkstoffe – Serelaxin| journal = Österreichische Apothekerzeitung| issue = 5/2013| page = 36| language = German}}</ref>
<ref name=Tousoulis>{{cite journal|last=Tousoulis|first=D|coauthors=Kampoli, A., Papageorgiou, C., Stefanadis, C.|title=The role of nitric oxide on endothelial function|journal=Curr Vasc Pharmacol|year=2012|volume=10|pages=4–18}}</ref>
<ref name="aerztezeitung">{{cite web|url=http://www.aerztezeitung.de/medizin/krankheiten/herzkreislauf/herzinsuffizienz/article/826906/fortschritt-sicht-schwangerschaftshormon-herzschwaeche.html?sh=1&h=-655181939|journal=ÄrzteZeitung|date=23 November 2012|title=Schwangerschaftshormon gegen Herzschwäche|trans_title=Pregnancy hormone against heart failure|author=Dirk Einecke}}</ref>
<ref name="pmid21613576">{{cite journal | author = Conrad KP | title = Maternal vasodilation in pregnancy: the emerging role of relaxin | journal = Am. J. Physiol. Regul. Integr. Comp. Physiol. | volume = 301 | issue = 2 | pages = R267–75 |date=August 2011 | pmid = 21613576 | pmc = 3154715 | doi = 10.1152/ajpregu.00156.2011 }}</ref>
<ref name="Bathgate">{{cite journal|last=Bathgate|first=R.|coauthors=Halls, M., van der Westhuizen, E., Callander, G., Kocan, M. et al|title=The Relaxin family peptides and their receptors|journal=Physiol Rev|year=2013|volume=93|pages=405–480}}</ref>
<ref name="Miyares">{{cite journal|last=Miyares|first=M|coauthors=Davis, K.|title=Serelaxin, a breakthrough investigational intravenous agent for acute heart failure|journal=P.T|year=2013|volume=38|pages=606–611}}</ref>
<ref name="Teichman1">{{cite journal|last=Teichman|first=S|coauthors=Unemori, E., Teerlink, J., Cotter, G., Metra, M.|title=Relaxin, review of biology and potential role in treating heart failure|journal=Curr Heart Fail Rep|year=2010|volume=75|pages=75–82}}</ref>
<ref name="Teichman2">{{cite journal|last=Teichman|first=S|coauthors=Unemori, E., Dschietzig, T., Conrad, K., Voors, A. et al|title=Relaxin, a pleiotropic vasodilator for the treatment of heart failure|journal=Heart Fail Rev|year=2009|volume=14|pages=321–329}}</ref>
<ref name="Ponikowski">{{cite journal|last=Ponikowski|first=P.|coauthors=Mitroic, V., Rude, M., Fernandez, A., Voors, A. et al|title=A randomized, double-blind, placebo controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure|journal=Eur Heart J|year=2014|volume=35|pages=431–441}}</ref>
<ref name="Shaw">{{cite journal|last=Shaw|first=E.|coauthors=Wood, P., Kulpa, J., Yang, F., Summerlee, A. et al|title=Relaxin alters cardiac myofilament function through a PKC-dependent pathway|journal=Am J Physiol Heart Circ Physiol|year=2009|volume=297|pages=29–36}}</ref>
<ref name="Du">{{cite journal|last=Du|first=X.|coauthors=Hewitson, T., Nguyen, M., Samuel, C.|title=Therapeutic effects of Serelaxin in acute heart failure|journal=Circ J|year=2014|volume=12|pages=6–19}}</ref>
<ref name="King">{{cite journal|last=King|first=A|title=Heart failure-promising data for Serelaxin|journal=Nat Rev Cardiol|year=2013|volume=10|page=3}}</ref>
<ref name="Filippatos">{{cite journal|last=Filippatos|first=G.|coauthors=Teerlink, J., Farmakis, D., Cotter, G., Davison, B. et al|title=Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial|journal=Eur Heart|year=2014|volume=89|pages=90–103}}</ref>
<ref name="Novartis">{{cite web|last=Novartis Global|title=FDA grants breakthrough designation to Novartis' serelaxin (RLX030) for acute heart failure|url=http://www.novartis.com/newsroom/media-releases/en/2013/1711047.shtml|publisher=Novartis Global}}</ref>
}}


{{Vasodilators used in cardiac diseases}}
{{Vasodilators used in cardiac diseases}}


[[Category:Cardiovascular Drugs]]
[[Category:Cardiovascular Drugs]]
[[Category:Drugs]]
[[Category:Drug]]
[[Category:Vasodilators]]
[[Category:Vasodilators]]

Latest revision as of 17:08, 20 August 2015

Serelaxin
Clinical data
Pregnancy
category
  • N/A
Routes of
administration
Intravenous
ATC code
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
ChemSpider
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC256H408N74O74S8
Molar mass5963 g/mol

WikiDoc Resources for Serelaxin

Articles

Most recent articles on Serelaxin

Most cited articles on Serelaxin

Review articles on Serelaxin

Articles on Serelaxin in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Serelaxin

Images of Serelaxin

Photos of Serelaxin

Podcasts & MP3s on Serelaxin

Videos on Serelaxin

Evidence Based Medicine

Cochrane Collaboration on Serelaxin

Bandolier on Serelaxin

TRIP on Serelaxin

Clinical Trials

Ongoing Trials on Serelaxin at Clinical Trials.gov

Trial results on Serelaxin

Clinical Trials on Serelaxin at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Serelaxin

NICE Guidance on Serelaxin

NHS PRODIGY Guidance

FDA on Serelaxin

CDC on Serelaxin

Books

Books on Serelaxin

News

Serelaxin in the news

Be alerted to news on Serelaxin

News trends on Serelaxin

Commentary

Blogs on Serelaxin

Definitions

Definitions of Serelaxin

Patient Resources / Community

Patient resources on Serelaxin

Discussion groups on Serelaxin

Patient Handouts on Serelaxin

Directions to Hospitals Treating Serelaxin

Risk calculators and risk factors for Serelaxin

Healthcare Provider Resources

Symptoms of Serelaxin

Causes & Risk Factors for Serelaxin

Diagnostic studies for Serelaxin

Treatment of Serelaxin

Continuing Medical Education (CME)

CME Programs on Serelaxin

International

Serelaxin en Espanol

Serelaxin en Francais

Business

Serelaxin in the Marketplace

Patents on Serelaxin

Experimental / Informatics

List of terms related to Serelaxin

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Kiran Singh, M.D. [2]

Overview

Serelaxin (RLX030) is an investigational drug for the treatment of acute heart failure (AHF), targeting the relaxin receptor. Serelaxin is a recombinant form of human relaxin-2, a hormone that (among other functions) is produced during pregnancy and mediates the haemodynamic changes that occur during this time, such as increased blood output of the heart and blood flow in the kidney. Human-relaxin-2 mediates vasodilation (widening of blood vessels) by increasing the production of nitric oxide (NO), a potent vasodilator. Activation of the relaxin receptor RXFP1 activates several enzymes in a phosphorylation cascade that eventually results in the activation of NO synthase in endothelial cells and the subsequent production of NO. Relaxin can also bind to a secondary receptor, endothelial B receptor, which is upregulated as a result of the previous pathway. Relaxin binding to endothelial B receptor on endothelial cells also induces vasodilation.

Relaxin causes vasodilation by an indirect mechanism, where it inhibits the potent vasoconstrictors angiotensin II and endothelin. In addition to vasodilation, the effects of relaxin are also seen in the kidneys, by significantly increasing creatinine clearance, which is a measure of kidney function, as well as increased renal blood flow. Relaxin also functions as a cardiac stimulant. Studies have demonstrated that relaxin increases calcium sensitivity of cardiac myofilaments as well as increasing phosphorylation of the myofilaments by protein kinase C (PKC). These modifications both function to increase the force generated by the myofilaments without increasing the energy consumption of the cardiac myocytes. Thus relaxin and serelaxin can increase stroke volume, the amount of blood pumped per heart beat, without increasing the energy demand on the already strained heart of acute heart failure patients.

Acute heart failure

Serelaxin is currently undergoing clinical trials in patients with acute heart failure, and is being developed by Novartis. Serelaxin has completed several clinical trials as a therapy for AHF. Phase I trials examined safety and tolerability, while phase II trials evaluated its haemodynamic effects and symptom relief. The Pre-RELAX-AHF phase II trial administered a dose of 30 µg/kg/day and showed a decrease in blood pressure, improved dyspnoea, and increased renal blood flow. In phase III the RELAX-AHF trial gave a 48hr intravenous infusion of the same dose. It significantly improved patients' dyspnoea, resulted in a 30% reduction in worsening of heart failure symptoms, a decreased hospital stay and a reduction in signs and symptoms of congestion. The FDA has granted serelaxin "breakthrough therapy" designation, meant to expedite the development and review of drugs for life threatening conditions and is set to be reviewed in February 2014.

References